SCHEMBL30008799

SCHEMBL30008799

O=S(=O)(Nc1ccc(-c2ncnc3[nH]ccc23)cc1)C1CCCCC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 5/20 0.55
IKBKB O14920 1/20 0.55
CHUK O15111 1/20 0.55
MAP2K4 P45985 2/20 0.52
SGK1 O00141 2/20 0.51
JAK2 O60674 4/20 0.49
JAK1 P23458 3/20 0.48
PIK3C3 Q8NEB9 1/20 0.46
JAK3 P52333 3/20 0.44
CIT O14578 1/20 0.44
CHEK1 O14757 1/20 0.44
AURKA O14965 1/20 0.44
DAPK3 O43293 1/20 0.44
PRKD3 O94806 1/20 0.44
MAP4K4 O95819 1/20 0.44
PAK4 O96013 1/20 0.44
ABL1 P00519 1/20 0.44
NTRK1 P04629 1/20 0.44
LCK P06239 1/20 0.44
CSF1R P07333 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30009888 0.81 PIK3C3 (0.69) IKBKBCHUKMAP2K4SGK1JAK2
SCHEMBL24805256 0.80 IKBKB (0.70) KITIKBKBCHUKJAK2JAK3
SCHEMBL30009491 0.78 PIK3C3 (0.67) IKBKBCHUKJAK2JAK1PIK3C3
SCHEMBL30009248 0.77 IKBKB (0.61) KITIKBKBCHUKJAK2JAK1
SCHEMBL20918980 0.76 JAK1 (0.81) JAK1
SCHEMBL30009334 0.76 IKBKB (0.60) KITIKBKBCHUKJAK2JAK1
SCHEMBL15665090 0.75 KIT (0.89) KIT
SCHEMBL30009538 0.75 KIT (0.69) KITIKBKBCHUKJAK2JAK1
SCHEMBL30008725 0.75 IKBKB (0.69) IKBKBCHUKJAK2JAK1PIK3C3
SCHEMBL15664518 0.74 KIT (0.72) KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US claimed
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor MAP3K20, MAP3K15, MAP3K1 KIT 3668/4885IKBKB 294/4885CHUK 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.